The cell-based assay is a method of obtaining quantitative data on the activity of single cells, either by electrophoresis or immunofluorescence techniques. As highly reproducible and cost-efficient laboratory instruments, customized and standard cell-based Assays are extensively used by researchers in a number of applications. Gene-specific and cell-based assay for the purpose of detecting, prioritizing, and otherwise validating the expression of specific genes in cancer cell lines and tissues has become a reality today. Using such a method can be important in the detection of potential biological activity associated with oncogenes and tumor suppressants that are resistant to conventional therapies.
Increasing prevalence of chronic disease cancer, diabetes, and CVD, and lifestyle disorders is expected to drive growth of the global cell-based assay market during the forecast period. According to the World Health Organization (WHO), in 2018, around 9.6 million deaths were attributed to cancer, of which 2.09 million cases were lung cancer. According to the WHO, around 17.9 million people die of cardiovascular diseases every year. Cell-based assays are commonly used for determining the biological activity of the drug product and drug substance. Thus, these factors are expected to drive growth of the global cell-based assay market during the forecast period. Furthermore, increasing investments in R&D for drug discovery is expected to propel the global cell-based assay market growth over the forecast period. Besides, rise in technological advancements in cell-based methodologies is expected to boost the global cell-based assay market growth over the forecast period.
However, high maintenance and operational costs combined with a lack of skilled personnel to operate these technologies are expected to hinder the global cell-based assay market growth over the forecast period. Among regions, North America is expected to witness significant growth in the global cell-based assay market during the forecast period. This is owing to high adoption of cell-based therapies and the presence of robust healthcare infrastructure in the region. Furthermore, Asia Pacific is expected to register a robust growth rate over the forecast period, owing to increasing awareness regarding these assays for drug discovery.
Key companies involved in the global cell-based assay market are Becton, Dickinson and Company, Promega Corporation, Bio-Rad Laboratories, Inc., Perkin Elmer Inc., Corning Inc., Merck KGaA, Danaher Corporation, F. Hoffmann-La Roche Ltd, and Thermo Fisher Scientific Inc.
For instance, in October 2020, Becton, Dickinson, and Company introduced a new assay BD Multitest 6-Color TBNK Reagent with BD Trucount Tubes for COVID-19 patients in Europe with CE mark.
No comments:
Post a Comment